Vasculitis and inflammatory arthritis.

Abstract

Vasculitis has been described in most types of inflammatory arthritis. The best described and most widely recognised form is rheumatoid vasculitis. The incidence of systemic rheumatoid vasculitis has declined significantly following the general early use of methotrexate in the 1990s, and it is now a rare form of vasculitis. Treatment of rheumatoid vasculitis is conventionally with glucocorticoids and cyclophosphamide, but there is an increasing role for rituximab similar to that in other types of vasculitis. Despite these developments the mortality of rheumatoid vasculitis remains high. Vasculitis in other types of inflammatory arthritis is less well described and the treatment remains empirical.

• Authors: Richard A Watts, David G I Scott
• Journal: Best practice & research. Clinical rheumatology (Best Pract Res Clin Rheumatol) Vol. 30 Issue 5 Pg. 916-931 (10 2016) ISSN: 1532-1770 [Electronic] Netherlands
• PMID: 27964796 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2016 Elsevier Ltd. All rights reserved.

Chemical References

• Antirheumatic Agents
• Glucocorticoids
• Rituximab
• Cyclophosphamide
• Methotrexate

Topics

• Antirheumatic Agents (therapeutic use)
• Arthritis, Rheumatoid (complications, drug therapy, pathology)
• Cyclophosphamide (therapeutic use)
• Glucocorticoids (therapeutic use)
• Humans
• Incidence
• Methotrexate (therapeutic use)
• Rituximab (therapeutic use)
• Vasculitis (drug therapy, epidemiology, etiology)